German pharma major Boehringer Ingelheim has taken over Swiss cancer immunotherapy player AMAL Therapeutics.
Up To Date
Latest News
French microalgae specialist Microphyt has raised €28.5m to develop its microalgae portfolio for nutrition and...
French biotech Osivax has raised €8m to fast-track development of its lead flu vaccine candidate – and branch...
It is one of the largest single private funding rounds a biotech company in Europe has ever pulled off. German...
Biophytis has priced its IPO on Nasdaq Paris. The company aims to raise up to €10.8m to advance its lead drug...
German biotech group Evotec has once more launched a spin-off: Breakpoint Therapeutics GmbH is focusing on...
Share
